AusperBio raises $73 million to advance hep B candidate
AusperBio has secured $73 million in a series B round to push forward clinical development of its lead program, AHB-137, for chronic hepatitis B.
The financing was led by HanKang Capital, with Sherpa Capital, CDH Investments, and a strategic investor joining. The funds will support Phase II development of AHB-137 in China and global trials, scale up manufacturing, and expand the company’s therapeutic pipeline.
Chief executive Guofeng Cheng said: “We are honored by our investors' confidence and support. This milestone financing recognizes our scientific and clinical accomplishments to date and enables us to accelerate our clinical programs and move closer to delivering a functional cure for CHB patients in need.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze